Triumph Capital Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
Other funds holding BIIB
Triumph Capital Management's BIIB Position: Q3 2026 in Review
Triumph Capital Management increased its Biogen (BIIB) stake by 300% in Q3 2026, buying an estimated $636 and bringing the position to 4 shares worth $904. The position accounts for ﹤0.01% of the portfolio, ranked #1717.
Triumph Capital Management first reported a position in BIIB in Q1 2026 and has held it in 3 quarters since. 1,062 funds tracked by Wall St. Rank hold BIIB as of Q3 2026.
- Triumph Capital Management held 4 shares of Biogen worth $904 as of Q3 2026.
- Triumph Capital Management bought 3 Biogen shares in Q3 2026, an estimated $636.
- Biogen made up ﹤0.01% of Triumph Capital Management's portfolio in Q3 2026, its #1717 holding.
- Triumph Capital Management first reported a position in Biogen in Q1 2026 and has held it in 3 quarters since.
- 1,062 funds tracked by Wall St. Rank held Biogen as of Q3 2026.
Based on Triumph Capital Management's 13F filing for Q3 2026, filed 14 Oct 2026.